SCHEMBL23461465

SCHEMBL23461465

CC(C)(SCC1CC1(F)F)C(NC(=O)c1ccc2ccccc2c1OCc1ccc(C(F)(F)F)cc1)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR2 P25025 6/20 0.53
▸ LMNA P02545 2/20 0.37
▸ DRD4 P21917 1/20 0.36
▸ SLC6A5 Q9Y345 3/20 0.35
▸ KDM4E B2RXH2 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ KIFC1 Q9BW19 1/20 0.34
▸ YAP1 P46937 1/20 0.34
▸ MME P08473 1/20 0.34
▸ ACE P12821 1/20 0.34
▸ CPA1 P15085 1/20 0.34
▸ ACE2 Q9BYF1 1/20 0.34
▸ PPARG P37231 1/20 0.33
▸ PPARD Q03181 1/20 0.33
▸ SENP5 Q96HI0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23461463 1.00 CXCR2 (0.53) CXCR2LMNADRD4SLC6A5KDM4E
SCHEMBL25189697 0.91 CXCR2 (0.43) CXCR2LMNAKDM4EALDH1A1GAA
SCHEMBL25189696 0.91 CXCR2 (0.43) CXCR2LMNAKDM4EALDH1A1GAA
SCHEMBL23461822 0.89 CXCR2 (0.41) CXCR2LMNAKDM4EALDH1A1GAA
SCHEMBL23461820 0.89 CXCR2 (0.41) CXCR2LMNAKDM4EALDH1A1GAA
SCHEMBL25548993 0.88 CXCR2 (0.60) CXCR2LMNADRD4SLC6A5KDM4E
SCHEMBL25553746 0.88 CXCR2 (0.60) CXCR2LMNADRD4SLC6A5KDM4E
SCHEMBL23460881 0.84 CXCR2 (0.55) CXCR2LMNADRD4SLC6A5KIFC1
SCHEMBL23460882 0.84 CXCR2 (0.55) CXCR2LMNADRD4SLC6A5KIFC1
SCHEMBL25549891 0.84 CXCR2 (0.64) CXCR2LMNADRD4SLC6A5KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed
WO-2021113806-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION (US) 2021-06-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159438-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA CXCR2 1205/4885LMNA 3155/4885DRD4 4290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback